Alta Capital Management LLC cut its holdings in Thermo Fisher Scientific Inc (NYSE:TMO) by 4.1% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 214,368 shares of the medical research company’s stock after selling 9,228 shares during the period. Thermo Fisher Scientific makes up 2.6% of Alta Capital Management LLC’s investment portfolio, making the stock its 19th biggest holding. Alta Capital Management LLC owned 0.05% of Thermo Fisher Scientific worth $40,558,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of the stock. APG Asset Management N.V. boosted its holdings in Thermo Fisher Scientific by 15.5% in the third quarter. APG Asset Management N.V. now owns 141,079 shares of the medical research company’s stock worth $26,692,000 after purchasing an additional 18,900 shares in the last quarter. Carnick & Kubik Group LLC bought a new stake in Thermo Fisher Scientific in the third quarter worth $1,384,000. Rockefeller Financial Services Inc. boosted its holdings in Thermo Fisher Scientific by 85.5% in the third quarter. Rockefeller Financial Services Inc. now owns 18,389 shares of the medical research company’s stock worth $3,479,000 after purchasing an additional 8,477 shares in the last quarter. Arcadia Investment Management Corp MI boosted its holdings in Thermo Fisher Scientific by 8.2% in the third quarter. Arcadia Investment Management Corp MI now owns 45,960 shares of the medical research company’s stock worth $8,696,000 after purchasing an additional 3,497 shares in the last quarter. Finally, Arrow Financial Corp boosted its holdings in Thermo Fisher Scientific by 81.5% in the third quarter. Arrow Financial Corp now owns 4,225 shares of the medical research company’s stock worth $800,000 after purchasing an additional 1,897 shares in the last quarter. Hedge funds and other institutional investors own 83.78% of the company’s stock.

A number of equities research analysts recently issued reports on the stock. Jefferies Group LLC reiterated a “hold” rating and issued a $195.00 price objective on shares of Thermo Fisher Scientific in a report on Thursday, September 28th. Zacks Investment Research upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $208.00 price target for the company in a report on Thursday, September 7th. Cleveland Research upgraded shares of Thermo Fisher Scientific from a “neutral” rating to a “buy” rating in a report on Thursday, July 20th. Argus restated a “buy” rating on shares of Thermo Fisher Scientific in a report on Tuesday, August 22nd. They noted that the move was a valuation call. Finally, Morgan Stanley restated an “overweight” rating and set a $220.00 price target on shares of Thermo Fisher Scientific in a report on Wednesday, September 6th. One investment analyst has rated the stock with a hold rating and sixteen have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $205.71.

In related news, VP Peter E. Hornstra sold 3,894 shares of the stock in a transaction dated Tuesday, September 5th. The shares were sold at an average price of $185.18, for a total value of $721,090.92. Following the completion of the transaction, the vice president now owns 19,751 shares of the company’s stock, valued at $3,657,490.18. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director C Martin Harris sold 360 shares of the stock in a transaction dated Wednesday, August 30th. The stock was sold at an average price of $180.97, for a total transaction of $65,149.20. Following the completion of the transaction, the director now directly owns 5,312 shares of the company’s stock, valued at approximately $961,312.64. The disclosure for this sale can be found here. In the last quarter, insiders sold 21,738 shares of company stock valued at $3,846,312. 0.49% of the stock is owned by corporate insiders.

COPYRIGHT VIOLATION NOTICE: This report was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this report on another publication, it was illegally stolen and republished in violation of US & international copyright and trademark legislation. The original version of this report can be accessed at https://www.thecerbatgem.com/2017/11/16/alta-capital-management-llc-sells-9228-shares-of-thermo-fisher-scientific-inc-tmo.html.

Shares of Thermo Fisher Scientific Inc (NYSE TMO) opened at $188.51 on Thursday. The company has a debt-to-equity ratio of 0.85, a current ratio of 1.26 and a quick ratio of 0.81. Thermo Fisher Scientific Inc has a one year low of $139.07 and a one year high of $201.20. The firm has a market cap of $75,820.21, a PE ratio of 20.78, a P/E/G ratio of 1.73 and a beta of 1.08.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Wednesday, October 25th. The medical research company reported $2.31 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.24 by $0.07. Thermo Fisher Scientific had a net margin of 11.73% and a return on equity of 15.94%. The business had revenue of $5.12 billion during the quarter, compared to analysts’ expectations of $5.03 billion. During the same quarter last year, the company earned $2.03 earnings per share. The firm’s revenue was up 13.9% on a year-over-year basis. research analysts forecast that Thermo Fisher Scientific Inc will post 9.36 EPS for the current year.

The business also recently announced a quarterly dividend, which will be paid on Monday, January 15th. Investors of record on Friday, December 15th will be paid a $0.15 dividend. This represents a $0.60 annualized dividend and a dividend yield of 0.32%. The ex-dividend date of this dividend is Thursday, December 14th. Thermo Fisher Scientific’s payout ratio is presently 10.19%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Stock Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related stocks with our FREE daily email newsletter.